

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Applicant** 

: Michaeli, et al.

Serial No.

: 10/613,377

Filed

: July 3, 2003

For

: LIPOSOMAL VACCINE

Examiner

: TBA

Group Art Unit

: 1614

#### First Class Mail

I hereby certify that this paper is being deposited with the United States Postal Service "First Class Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 in an envelope addressed to: Mail Stop No Fee, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450

on March 16, 2004

ANILIONIS

Name of person mailing paper or fee

ighature of person mailing paper or fee

Mail Stop No Fee

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### **INFORMATION DISCLOSURE STATEMENT**

Sir:

This communication is submitted in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. Consideration of the documents cited on the attached Form PTO/SB/08A is respectfully requested. Copies of the documents are provided herewith.

Serial No. 10/613, 377

Filed: July 3, 2003

Docket No. 1102865-0059

Page 2 of 2

TIME OF TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(3)

believed to be before the mailing date of the first Office Action on the merits, and therefore no

fee should be due. However, if a fee is required, the Commissioner is authorized to charge such

fee to Deposit Account No. 23-1703.

Dated: March 16, 2004

Respectfully submitted,

Reg. No. 36,995

Attorney for Applicant(s)

Customer No. 007470

Direct Dial: (212) 819-8248

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitut or form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of Sheet

Complete if Known					
Application Number	10/613,377				
Filing Date	July 3, 2003				
First Named Inventor	Michaeli, et al.				
Art Unit	1614				
Examiner Name	TBA				
Attorney Docket Number	1102865-0059				

		U.S. P	ATENT DOCU	MENTS		
Examiner	Cite	Document Number	Publication Date	Name of Patentee	Pages, Columns, Lines, Whe	
Initials*	No.1	Number-Kind Code <sup>2 (Ifknown)</sup>	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages/Figures Ap	pear
		5,023,077	June 11, 1991	Gevas, et al.		
	_	5,468,494	Nov. 21, 1995	Gevas, et al.		
		5,688,506	Nov. 18, 1997	Grimes, et al.		
		6,132,720	Oct. 17, 2000	Grimes, et al.		
		5,919,480	Jul. 6, 1999	Kedar et al.		
		4,767,842	Aug. 30, 1988	Stevens		
		5,698,201	Dec. 16, 1997	Stevens		
		6,359,114	Mar. 19, 2002	Grimes et al.		
		4,235,871	Nov. 25, 1980	Papahadjopoulos et al.		
		5,225,212	Jul. 6, 1993	Martin et al.		
		6,071,534	Jun. 6, 2000	Kim et al.		_
		5,962,016	Oct. 5, 1999	Willis		
-		6,090,406	Jul. 18, 2000	Popescu et al.		
		5,916,588	Jun. 29, 1999	Popescu et al.		
		5,013,556	May 7, 1991	Woodle et al.		
		Re: 35,338	Sep. 24, 1996	Haynes		
		5,100,662	Mar. 31, 1992	Bolcsak et al.		
		6,132,766	Oct. 17, 2000	Sankaram et al.		
		5,312,620	May 17, 1994	Ribi		
		5,376,369	Dec. 27, 1994	Allison et al.		
		5,292,506	Mar. 8, 1994	Oki et al.		
		5,292,524	Mar. 8, 1994	Male et al.		
			N PATENT DO		,	
Examiner	Cite	Foreign Patent Document	Publication Date		Pages, Columns, Lines, Where	
Initials*	No.'	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		EP 0 485 143 A1	5-13-92	Boomen	I iguies Appear	┢─
		WO 93/19781	10-14-93			┡
	+			<del>  </del>		<u> </u>
		WO 01/34192	5-17-01			<u> </u>
	-	WO 99/59628	11-25-99			<u> </u>
	ļ	WO 02/076499	10-3-02			<u>_</u>
		WO 92/04009	19-3-92			L.
		WO 92/03162	5-3-92			
		WO 92/00081	9-1-92			
		WO 95/17211	20-6-95			Ī
	_	WO 95/04524	16-2-95			
	<u> </u>	EP 0 317 803	31-5-89			m
		EP 0 526 700	10-2-93	<del></del>		一
						ļ
		WO 92/14448	3-9-92			⊨
	4	WO 94/21235	29-9-94			
<del></del>	<u> </u>	WO 95/04523	16-2-95			L

27-01-82

EP 0 044 710

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respon

Substitute for form 1449/PTO
INFORMA

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of Sheet

Con	nplete if Known
Application Number	10/613,377
Filing Date	July 3, 2003
First Named Inventor	Michaeli, et al.
Art Unit	1614
Examiner Name	TBA
Attorney Docket Number	1102865-0059

Examiner Initials*	Cite No.					
	1	G. Gregoriadis (ed.), Lipsosome Technology, vol. 1, 2 <sup>nd</sup> ed., CRC Press, Boca Raton, FL. 1993, pp. 527-616				
		J.C. Cox et al. "Adjuvants – a classification and review of their modes of action" in Vaccine 1997 Vol. 15 (13): 248-256.				
•		Watson et al. Exp. Opin. Biol. Ther 2001, 1 (2): 309-317				
		A. Adler, Cancer Biother. 10: 293, 1995				
		Peterson G. L. 1983. "Determination of total protein." Methods Enzymol. 91: 95-119				
		Bartlett, G. R. 1959; and "Phosphorus assay in column chromatography" J. Biol. Chem. 234 : 446-468				
		S. Amselem et al. "Journal of Pharmaceutical Sciences" 1990, Vol. 79, Number 12				
		D. Liu et al., "Biochimica et Biophysica Acta, 1022 (1990) 348-354				
	<del>                                     </del>	G. Blume et al., Biochimica et Biophysica Acta, 1149 (1993) 180-184				
		A. L. Klibanov et al. in, Journal of Liposome Research 2(3), 321-334 (1992)				
		K. J. Williams, et al. in "Pathologic Basis of Disease" Stanley L. Robbins, et al. (1984) 417-431				
		A. J. Bretland, et al. Synergy: Cell Proliferation 34 (4), 199-210 (2001)				
··········		S.H. Ali, et al. Synergy: Cell Proliferation 34 (4), 223-231 (2001)				
		A. Pessina, et al. Synergy: Cell Proliferation 34 (4), 243-252 (2001)				
	-					
Examiner Si	nature	Date Considered	_			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant 's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspn.gov">www.uspn.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.15). For Japanese patent documents, the indication of the patent document under WIPO Standard ST.16 if possible. "Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.91. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.